NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Ligand Pharmaceuticals Incorporated (LGND) Stock Analysis

Ligand Pharmaceuticals Incorporated (LGND) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

LGND

$285.60

−$4.14 (−1.43%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LGND with… →

LGND Key Statistics

As of Sep 4, 2026
Trading
Open
$287.41
Previous Close
$289.74
Day's Range
285.47–290.00
52-Week Range
161.82–326.63
Volume
132.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.98
Valuation
Market Cap
$5.69B
P/E Ratio
29.84
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
23.93
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.53
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
19.60
EPS (ttm)Profit attributable to each share over the last twelve months.
9.57
Financials (FY)
Revenue (FY)
$268.09M+60.40%
Net Income (FY)
$124.45M
Profit marginThe share of revenue left as profit after all costs and taxes.
67.88%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
19.94M
1-Year Return
+70.26%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
360.07K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LGND Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+51.06%
2025+76.45%
2024+50.03%
2023+6.92%
2022−30.67%
2021+55.31%
2020−4.64%
2019−23.15%
2018−0.90%
2017+34.76%
2016 (partial year)−13.49%

As of September 4, 2026.

LGND Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$268.09M$124.45M46.4%
2024$167.13M−$4.03M−2.4%
2023$131.31M$52.15M39.7%
2022$196.25M−$33.36M−17.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$268.09M$253.54M$47.20M$124.45M46.4%
2024$167.13M$156.06M$23.02M−$4.03M−2.4%
2023$131.31M$120.80M$9.82M$52.15M39.7%
2022$196.25M$143.42M$3.04M−$33.36M−17.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LGND Valuation vs Biotechnology Median

Median of 656 stocks
MetricLGNDBiotechnology medianvs median
P/E29.8412.57137% above
P/S ratio19.6015.2628% above
Profit margin67.88%0.00%67.9 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Ligand Pharmaceuticals Incorporated (LGND) at $5.69B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 47.

The 52-week range on file runs from $161.82 to $326.63. LGND last closed at $285.60 on September 4, 2026. That is −$4.14 (−1.43%) against the previous close. The latest close sits 76.49% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $268.09M. That is +60.40% against the prior fiscal year, when revenue was $167.13M. Net income for the same year was $124.45M. Profit margin runs at 67.88%. That is 67.9 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 9.57.

Across the 4 fiscal years on file, revenue moves from $196.25M in 2022 to $268.09M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 29.84. That is 137.39% above the Biotechnology median of 12.57. The forward P/E on file is 23.93. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.53. The price-to-sales ratio is 19.6. On price-to-sales that is 28.39% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +70.26%. Measured over 10 years, that is +15.73% a year compounded. The reported beta is 0.98. Annualized volatility over the trailing 10 years is 45.84%.

Growth & Income

The record shows no dividend for LGND.

Across the complete calendar years on file, 2025 returned +76.45% and 2022 returned −30.67%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +51.06% year to date.

Peer Comparison

Ligand Pharmaceuticals Incorporated (LGND) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ligand Pharmaceuticals Incorporated LGND $5.69B 29.8
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Ligand Pharmaceuticals Incorporated trades at a P/E of 29.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Visit website →